Gene Validity Curation

Gene Validity Classification Summary

Gene/Disease Pair:

COX10 : Leigh syndrome

HGNC:2260 | MONDO_0009723
Mode of Inheritance: Autosomal recessive inheritance (HP:0000007)
Expert Panel: Mitochondrial Diseases
SOP: Gene Clinical Validity Standard Operating Procedures (SOP), Version 6

Genetic Evidence
Case-Level Data
Evidence Type Case Information Type Guidelines Points PMIDs/Notes
Default Range Max Count Total Counted
Variant Evidence
Autosomal Dominant or X-linked Disorder Variant is de novo 2 0-3 12
Proband with predicted or proven null variant 1.5 0-2 10
Proband with other variant type with some evidence of gene impact 0.5 0-1.5 7
Autosomal Recessive Disease Two variants in trans and at least one de novo or a predicted/proven null variant 2 0-3 12 1
2
3.5
Coenen MJ et al. 2004 Oct (PMID:15455402);
Two variants (not predicted/proven null) with some evidence of gene impact in trans 1 0-1.5 1
1.5
Antonicka H et al. 2003 Oct 15 (PMID:12928484);
Segregation Evidence   Summed LOD Family Count  
Candidate gene sequencing
Exome/genome or all genes sequenced in linkage region
Total Summed LOD Score    
Case-Control Data
Case-Control Study Type Case-Control Quality Criteria Guidelines Points PMIDs/Notes
Points/Study Max Count Points Counted
Single Variant Analysis 1. Variant Detection Methodology
2. Power
3. Bias and confounding
4. Statistical Significance
0-6 12
Aggregate Variant Analysis 0-6
Total Genetic Evidence Points (Maximum 12) 3.5
Experimental Evidence
Evidence Category Evidence Type Guidelines Points PMIDs/Notes
Default Range Max Count Total Counted
Function Biochemical Function 0.5 0 - 2 2 1
1
1.5
Nobrega MP et al. 1990 Aug 25 (PMID:2167310);
Protein Interaction 0.5 0 - 2
Expression 0.5 0 - 2 1 0.5
Uhlén M et al. 2015 Jan 23 (PMID:25613900);
Functional Alteration Patient cells 1 0 - 2 2 2
1.5
1.5
Williams SL et al. 2004 Feb 27 (PMID:14607829); Pitceathly RD et al. 2013 Dec (PMID:24100867);
Non-patient cells 0.5 0 - 1
Models Non-human model organism 2 0 - 4 4 1 3 3
Fukui H et al. 2007 Aug 28 (PMID:17715058);
Cell culture model 1 0 - 2
Rescue Rescue in human 2 0 - 4
Rescue in non-human model organism 2 0 - 4
Rescue in cell culture model 1 0 - 2
Rescue in patient cells 1 0 - 2
Total Experimental Evidence Points (Maximum 6) 6

 


 

Assertion criteria Genetic Evidence (0-12 points) Experimental Evidence
(0-6 points)
Total Points
(0-18)
Replication Over Time (Y/N)
Description Case-level, family segregation, or case-control data that support the gene-disease association Gene-level experimental evidence that support the gene-disease association Sum of Genetic & Experimental
Evidence
> 2 pubs w/ convincing evidence over time (>3 yrs)
Assigned Points 3.5 6 9.5 NO
CALCULATED CLASSIFICATION LIMITED 1-6
MODERATE 7-11
STRONG 12-18
DEFINITIVE 12-18 AND replication over time
Valid contradictory evidence (Y/N)*
NO
CALCULATED CLASSIFICATION (DATE)
Moderate
05/20/2019
EXPERT CURATION (DATE)
Moderate
05/20/2019
EVIDENCE SUMMARY
The relationship between COX10 and Leigh syndrome spectrum was evaluated using the ClinGen Clinical Validity Framework as of April 22, 2019. 14 articles were reviewed. COX10 was first reported in relation to autosomal recessive Leigh syndrome spectrum in 2003 (Antonicka et al., PMID: 12928484). Six unique variants predicted to cause a loss of or reduced function of the protein have been reported in ClinVar. Complex IV deficiency is the mechanism of disease for this gene. Evidence supporting this gene-disease relationship includes case-level data and experimental data. Variants in this gene have been reported in at least 2 probands with Leigh syndrome spectrum in 2 different publications (PMID 12928484, 15455402). This gene-disease association is further supported by the function of the gene product, expression, and studies in patient cell lines and COX10 mouse models. In summary, there is moderate evidence to support the relationship between COX10 and autosomal recessive Leigh syndrome spectrum. This classification was approved by the NICHD U24 ClinGen Mitochondrial Disease Gene Curation Expert Panel on April 22, 2019 (SOP Version 6).